Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹739Prev. Close
₹736.85Turnover(Lac.)
₹1,028.02Day's High
₹739.95Day's Low
₹724.9552 Week's High
₹77552 Week's Low
₹318.75Book Value
₹153.56Face Value
₹1Mkt Cap (₹ Cr.)
11,711.74P/E
371.57EPS
1.98Divi. Yield
0.68Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 15.93 | 15.93 | 15.93 | 15.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,398.62 | 1,265.89 | 1,266.52 | 2,591.37 |
Net Worth | 2,414.55 | 1,281.82 | 1,282.45 | 2,607.3 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 2,709.49 | 3,139.9 | 3,306.32 | 2,491.22 |
yoy growth (%) | -13.7 | -5.03 | 32.71 | -6.2 |
Raw materials | -1,450.36 | -1,684.42 | -1,780.39 | -1,307.02 |
As % of sales | 53.52 | 53.64 | 53.84 | 52.46 |
Employee costs | -220.67 | -264.9 | -264.41 | -226.3 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 273.16 | 300.54 | 367.69 | 114.52 |
Depreciation | -99.97 | -107.39 | -82.59 | -81.12 |
Tax paid | -58.69 | 22.3 | -104.25 | -35.32 |
Working capital | -964.78 | 534.81 | -82.75 | -63.88 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -13.7 | -5.03 | 32.71 | -6.2 |
Op profit growth | 15.13 | -31.21 | 69.57 | 1.83 |
EBIT growth | -14.14 | -13.15 | 74.13 | 0.6 |
Net profit growth | -33.21 | 21.9 | 232.65 | 8.48 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Other Operating Income | 58.1 | 62.4 | 70.99 | 134.66 | 132.94 |
Other Income | 92.8 | 50.6 | 11.29 | 290.64 | 257.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,520 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,559.2 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,478.4 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,099.05 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,475.05 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Shyam S Bhartia
Co-Chairman & Non-Exe.Director
Hari S Bhartia
Non-Exec. & Independent Dir.
S Sridhar
Non-Exec. & Independent Dir.
Sudha Pillai
Non-Exec. & Independent Dir.
Ashok Misra
Non-Exec. & Independent Dir.
Vivek Mehra
Non-Exec. & Independent Dir.
SUSHIL KUMAR ROONGTA
Managing Director
Priyavrat Bhartia
Joint Managing Director
Arjun Shanker Bhartia
Non-Exec. & Independent Dir.
Arun Seth
Whole Time Director & CFO
Arvind Chokhany
Company Sec. & Compli. Officer
Naresh Kapoor
Whole Time Director
R Kumar
Independent Director
Shirish Gundopant Belapure
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Jubilant Pharmova Ltd
Summary
Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs. The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions. . Proprietary novel drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases. The Company was incorporated in 21st June, 1978. The Company tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983, the companys commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JLSL had in
Read More
The Jubilant Pharmova Ltd shares price on nse is Rs.₹735.2 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jubilant Pharmova Ltd is ₹11711.74 Cr. as of 03 Jul ‘24
The PE and PB ratios of Jubilant Pharmova Ltd is 371.57 and 4.94 as of 03 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Jubilant Pharmova Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Jubilant Pharmova Ltd is ₹318.75 and ₹775 as of 03 Jul ‘24
Jubilant Pharmova Ltd's CAGR for 5 Years at 11.42%, 3 Years at 0.64%, 1 Year at 82.98%, 6 Month at 27.49%, 3 Month at 25.01% and 1 Month at 9.71%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.